GlassScriptPhysician profile
Joseph R Weinstein
NPI 1437231826
$3,916.38
in general payments reported to CMS, 2019-2025
29 companies · $873 in 2025
The $873 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $666 · 2021: $113 · 2022: $77.84 · 2023: $412 · 2024: $762 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,047.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $812.00 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $627.23 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $341.94 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $291.76 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Lilly USA, LLC | $202.89 | 2019-2025 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $197.52 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.93 | 2019-2023 | Synjardy |
| Glaxosmithkline, LLC. | $174.17 | 2022-2024 | Shingrix, Arexvy |
| Abiomed | $149.58 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $110.12 | 2024-2025 | |
| Daiichi Sankyo INC. | $89.94 | 2019-2020 | |
| Inspire Medical Systems, INC. | $89.24 | 2024-2025 | Inspire |
| Janssen Pharmaceuticals, INC | $62.99 | 2019 | |
| Abbott Laboratories | $62.25 | 2023-2024 | Freestyle Libre 3, Eterna |
| Allergan, INC. | $61.40 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $60.79 | 2019-2023 | Repatha, Otezla |
| Genentech USA, INC. | $56.52 | 2019-2020 | |
| Amarin Pharma, INC. | $55.89 | 2019-2020 | |
| Exact Sciences Corporation | $54.24 | 2024-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $43.08 | 2020-2023 | Contrave |
| Coloplast Corp | $31.97 | 2019 | |
| Globus Medical, INC. | $29.10 | 2025 | Senza |
| Astellas Pharma US INC | $25.48 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.47 | 2019 | |
| Boston Scientific Corporation | $20.19 | 2025 | Ams 700 |
| Ibsa Pharma INC. | $18.43 | 2025 | Flector, Tirosint, Licart |
| Sanofi Pasteur INC. | $13.50 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.47 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.